FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2097900911> ?p ?o ?g. }

• W2097900911 endingPage "97" @default.
• W2097900911 startingPage "91" @default.
• W2097900911 abstract "Non–small-cell lung cancer (NSCLC) accounts for approximately 80%-85% of all cases of lung cancer; for patients with stage III disease, it accounts for approximately 40% of all cases. The treatment for unresectable stage III NSCLC is the combination of platinum-based chemotherapy and thoracic radiation. In this article, new targeted agents under investigation for possible integration into the combined therapy are reviewed. One of the most promising strategies is the inhibition of the epidermal growth factor receptor (EGFR) pathway. Radiation activates EGFR signaling, leading to radio-resistance by inducing cell proliferation and enhanced DNA repair. Several preclinical models have shown synergistic activity when cetuximab was combined with radiation therapy. Some phase II trials have evaluated the safety and efficacy of synchronous cetuximab and radiation therapy with promising results. Gefitinib has a radiosensitizing effect on cell lines and has been investigated in combination with radiation therapy for unresectable stage III NSCLC. However, disappointing results were observed in the maintenance treatment with gefitinib after chemoradiation therapy. Erlotinib has been tested in a phase I trial with chemoradiation therapy. Radiation induces tumor death by damaging cell membranes, DNA, and microvascular endothelial cells, which in response increase proangiogenic growth factors. Antiangiogenic agents reduce vascular density but improve tumor oxygenation. Use of vascular endothelial growth factor receptor (VEGFR) inhibitors enhances the therapeutic efficacy of irradiation in human NSCLC by hindering the repair of sublethal radiation damage. Trials combining erlotinib and bevacizumab with thoracic radiation are ongoing. New strategies must be developed for the integration of this triple-combination treatment. As radiation therapy enhances HSP90 chaperone function, causing radio-resistant lung cancer cells, therapeutic agents that block this path are likely candidates for decreasing radio-resistance by suppressing HIF-1α and VEGF expression and thus inhibiting the survival and angiogenic potential of lung cancer cells. Aurora kinase inhibitors with radiation therapy seem to have an additive effect in preclinical models in NSCLC and mesothelioma." @default.
• W2097900911 created "2016-06-24" @default.
• W2097900911 creator A5003261938 @default.
• W2097900911 creator A5043033718 @default.
• W2097900911 creator A5085499011 @default.
• W2097900911 creator A5090038152 @default.
• W2097900911 date "2010-03-01" @default.
• W2097900911 modified "2023-10-14" @default.
• W2097900911 title "New Molecular Targeted Therapies Integrated With Radiation Therapy in Lung Cancer" @default.
• W2097900911 cites W1510479634 @default.
• W2097900911 cites W1773536029 @default.
• W2097900911 cites W1975901555 @default.
• W2097900911 cites W1989761818 @default.
• W2097900911 cites W2002812365 @default.
• W2097900911 cites W2007287727 @default.
• W2097900911 cites W2010238802 @default.
• W2097900911 cites W2018514409 @default.
• W2097900911 cites W2022071509 @default.
• W2097900911 cites W2024488606 @default.
• W2097900911 cites W2050980183 @default.
• W2097900911 cites W2063618899 @default.
• W2097900911 cites W2063806011 @default.
• W2097900911 cites W2071394735 @default.
• W2097900911 cites W2072247333 @default.
• W2097900911 cites W2074918415 @default.
• W2097900911 cites W2086560827 @default.
• W2097900911 cites W2099803844 @default.
• W2097900911 cites W2101927575 @default.
• W2097900911 cites W2106979625 @default.
• W2097900911 cites W2107591221 @default.
• W2097900911 cites W2108628793 @default.
• W2097900911 cites W2109252212 @default.
• W2097900911 cites W2110469369 @default.
• W2097900911 cites W2110604215 @default.
• W2097900911 cites W2110835998 @default.
• W2097900911 cites W2115538252 @default.
• W2097900911 cites W2118113452 @default.
• W2097900911 cites W2123766085 @default.
• W2097900911 cites W2126427337 @default.
• W2097900911 cites W2127101185 @default.
• W2097900911 cites W2128553601 @default.
• W2097900911 cites W2133461110 @default.
• W2097900911 cites W2134931983 @default.
• W2097900911 cites W2136284645 @default.
• W2097900911 cites W2139806098 @default.
• W2097900911 cites W2142007209 @default.
• W2097900911 cites W2142550892 @default.
• W2097900911 cites W2142850084 @default.
• W2097900911 cites W2143180849 @default.
• W2097900911 cites W2143842256 @default.
• W2097900911 cites W2145140423 @default.
• W2097900911 cites W2145304942 @default.
• W2097900911 cites W2145653040 @default.
• W2097900911 cites W2152452482 @default.
• W2097900911 cites W2152649141 @default.
• W2097900911 cites W2152755651 @default.
• W2097900911 cites W2153850465 @default.
• W2097900911 cites W2153865661 @default.
• W2097900911 cites W2154398592 @default.
• W2097900911 cites W2155384808 @default.
• W2097900911 cites W2155838479 @default.
• W2097900911 cites W2160475600 @default.
• W2097900911 doi "https://doi.org/10.3816/clc.2010.n.012" @default.
• W2097900911 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20199974" @default.
• W2097900911 hasPublicationYear "2010" @default.
• W2097900911 type Work @default.
• W2097900911 sameAs 2097900911 @default.
• W2097900911 citedByCount "58" @default.
• W2097900911 countsByYear W20979009112012 @default.
• W2097900911 countsByYear W20979009112013 @default.
• W2097900911 countsByYear W20979009112014 @default.
• W2097900911 countsByYear W20979009112015 @default.
• W2097900911 countsByYear W20979009112016 @default.
• W2097900911 countsByYear W20979009112017 @default.
• W2097900911 countsByYear W20979009112018 @default.
• W2097900911 countsByYear W20979009112019 @default.
• W2097900911 countsByYear W20979009112020 @default.
• W2097900911 countsByYear W20979009112021 @default.
• W2097900911 countsByYear W20979009112023 @default.
• W2097900911 crossrefType "journal-article" @default.
• W2097900911 hasAuthorship W2097900911A5003261938 @default.
• W2097900911 hasAuthorship W2097900911A5043033718 @default.
• W2097900911 hasAuthorship W2097900911A5085499011 @default.
• W2097900911 hasAuthorship W2097900911A5090038152 @default.
• W2097900911 hasConcept C121608353 @default.
• W2097900911 hasConcept C126322002 @default.
• W2097900911 hasConcept C143998085 @default.
• W2097900911 hasConcept C2776256026 @default.
• W2097900911 hasConcept C2776694085 @default.
• W2097900911 hasConcept C2776999253 @default.
• W2097900911 hasConcept C2777506169 @default.
• W2097900911 hasConcept C2777802072 @default.
• W2097900911 hasConcept C2778087573 @default.
• W2097900911 hasConcept C2779438470 @default.
• W2097900911 hasConcept C2779998722 @default.
• W2097900911 hasConcept C2780580887 @default.
• W2097900911 hasConcept C502942594 @default.
• W2097900911 hasConcept C509974204 @default.

• next